BioCardia, Inc. (BCDA)
NASDAQ: BCDA · Real-Time Price · USD
1.395
-0.065 (-4.45%)
At close: Oct 23, 2025, 4:00 PM EDT
1.400
+0.005 (0.36%)
After-hours: Oct 23, 2025, 7:57 PM EDT
BioCardia Employees
As of December 31, 2024, BioCardia had 20 total employees, including 16 full-time and 4 part-time employees. The number of employees did not change compared to the previous year.
Employees
20
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$439,700
Market Cap
14.80M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 20 | 0 | - |
| Dec 31, 2023 | 20 | -16 | -44.44% |
| Dec 31, 2022 | 36 | 1 | 2.86% |
| Dec 31, 2021 | 35 | 6 | 20.69% |
| Dec 31, 2020 | 29 | 5 | 20.83% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2014 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
BCDA News
- 21 days ago - BioCardia Regains Compliance with Nasdaq Listing Requirements - GlobeNewsWire
- 5 weeks ago - BioCardia Announces Pricing of Up To $12 Million Public Offering - GlobeNewsWire
- 5 weeks ago - BioCardia Announces CardiAMP Chronic Myocardial Ischemia Trial Top Line Data of Roll-in Cohort Show Improved Exercise Tolerance and Reduced Angina Episodes at Six-Month Primary Follow-up - GlobeNewsWire
- 7 weeks ago - BioCardia CEO Peter Altman to Present at the H. C. Wainwright 27th Annual Global Investment Conference in New York City September 8-10, 2025 - GlobeNewsWire
- 2 months ago - BioCardia, Inc. (BCDA) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - BioCardia Reports Second Quarter 2025 Business Highlights and Financial Results - GlobeNewsWire
- 2 months ago - BioCardia to Host Q2 2025 Corporate Update and Financial Results Conference Call on August 11, 2025 - GlobeNewsWire
- 2 months ago - BioCardia Provides Update on Timing of Regulatory Activities Seeking FDA Approval and Japan PMDA Approval for CardiAMP® Cell Therapy for Heart Failure and Helix™ Transendocardial Delivery Catheter - GlobeNewsWire